| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/01/2006 | CN1739641A Sheng'an capsule with function of improving sleep quality and its prepn |
| 03/01/2006 | CN1739637A Chinese herbal medicine decoction for treating primary cold-type sciatica and its prepn |
| 03/01/2006 | CN1739594A Nao'an oral liquid and its prepn |
| 03/01/2006 | CN1739581A Naoxinshu dripping pill and its prepn process |
| 03/01/2006 | CN1739502A Application of benzydalysine in preparing medicine for treating diabetic peripheral neuropathy |
| 03/01/2006 | CN1739501A Coated thioctic acid tablet for treating and controlling diabetic neural lesion |
| 03/01/2006 | CN1739500A (-)-epigallocatechin gallate-magnesium complex solid dispersion and its prepn and application |
| 03/01/2006 | CN1739496A Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders |
| 03/01/2006 | CN1243770C Neurotrophic growth factor |
| 03/01/2006 | CN1243768C Application of steroid saponin for preventing and curing senile dementia and novel steroid saponin |
| 03/01/2006 | CN1243753C Substituted 3,4-dihydro-pyrimido[1,2-A] pyrimidines and 3,4-dihydropyrazino [1,2-A] pyrimidines |
| 03/01/2006 | CN1243751C Piperidine compounds as anti-allergic medicine |
| 03/01/2006 | CN1243750C 4-,5-,6-and 7-indole derivatives useful for treatment of CNS disorders |
| 03/01/2006 | CN1243747C Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme IKK-2 |
| 03/01/2006 | CN1243735C 2-lminopyrrolidine derivatives |
| 03/01/2006 | CN1243734C Pharmaceutical use of Bafuluomaidi |
| 03/01/2006 | CN1243730C Cinnamoylaminoalkyl-substd. benzenesulfonamide derivs. |
| 03/01/2006 | CN1243721C Substituted amino compounds and their use as substances having analgesic effect |
| 03/01/2006 | CN1243555C Medicine for treating neurasthenia and preparing method and use |
| 03/01/2006 | CN1243552C Functional medical wine for treating various diseases |
| 03/01/2006 | CN1243550C Pharmaceutical compositions and uses for androst-5-ene-3beta, 17 beta-diol and use thereof |
| 03/01/2006 | CN1243540C Combination of active principles for treating senile dementia such as alzheimer dementia |
| 02/28/2006 | US7005553 such as 2-nitrophenol by reacting 3-hydroxy-4-methoxybenzophenone with alkyl nitrate in presence of regioselective acid catalyst (sulfuric acid) |
| 02/28/2006 | US7005516 Derivatives of monosaccharides as cell adhesion inhibitors |
| 02/28/2006 | US7005452 administering enantiomorphs comprising (Z(+-)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride), as serotonin and adrenergic uptake inhibitors, with side effect reduction; antidepressants |
| 02/28/2006 | US7005436 Heterocyclo inhibitors of potassium channel function |
| 02/28/2006 | US7005433 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 02/28/2006 | US7005432 Central nervous system disorder; antidepressants; analgesics |
| 02/28/2006 | US7005431 Imidazo-triazine derivatives as ligands for gaba receptors |
| 02/28/2006 | US7005422 Derivatives of monosaccharides as cell adhesion inhibitors |
| 02/28/2006 | US7005415 Wherein the DNA synthesis promoting activity of the heparin-binding protein is increased by the covalently bonded sugar chain which can be heparan sulfate; improved in vivo stabilities such as acid resistance and alkali resistance |
| 02/28/2006 | US7005285 Human p21-activated kinase 5 polypeptide |
| 02/28/2006 | US7005255 Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| 02/28/2006 | US7005138 Intravaginal or rectal delivery of selected serotonin reuptake inhibitors (ssris); antidepressants, analgesics, treating psychological disorders, pre-menstrual dysphoric disorder and obsessive compulsive disorders |
| 02/28/2006 | US7005122 Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route |
| 02/28/2006 | US7005121 Arerosol; heating drug, vaporization, cooling |
| 02/28/2006 | CA2347469C Esters of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 100,907 |
| 02/28/2006 | CA2331877C Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them |
| 02/23/2006 | WO2006020156A2 Heterocyclic dye compounds for in vivo imaging and diagnosis of alzheimer’s disease |
| 02/23/2006 | WO2006019673A2 Jiadifenin analogs and uses thereof |
| 02/23/2006 | WO2006018850A2 Compositions for treating amyloid associated diseases |
| 02/23/2006 | WO2006018657A1 Hdac inhibitors and methods of use thereof |
| 02/23/2006 | WO2006018538A1 Medicament for the treatment of central nervous system disorders |
| 02/23/2006 | WO2006018308A1 5-ht7 receptor antagonists |
| 02/23/2006 | WO2006017994A1 An analgesic pharmaceutical composition |
| 02/23/2006 | WO2006004507A3 New benzothiazole derivatives useful for treating cns disorders |
| 02/23/2006 | WO2006004386A8 Use of ginkgo biloba extract for the preparation of a medicine that is used to treat parkinson's disease |
| 02/23/2006 | US20060041139 Antagonists for melanin concentrating hormone-1 receptors; antidepressants, anxiolytic agents; incontinence, obesity |
| 02/23/2006 | US20060041138 Process for producing paroxetine hydrochloride hydrate |
| 02/23/2006 | US20060041125 Substituted pyrido-pyridazine derivatives which enhance cognition via the gaba-a receptors |
| 02/23/2006 | US20060041001 Useful in the treatment of diseases or conditions susceptible to adrenergic regulation controlled by alpha-2 adrenergic receptors |
| 02/23/2006 | US20060040992 Antiinflammatory 3-arylthio-3-thiazolyl-alkylamines |
| 02/23/2006 | US20060040987 "soft" analog of fentanyl; derivative of 1,4-disubstituted piperdine compounds; opioid receptor agonist; analgesic; high degree of efficiency against extreme pain; less side effects then fentanyl; oral bioavailability |
| 02/23/2006 | US20060040981 Use of phosphodiesterase-4 inhibitors as enhancers of cognition |
| 02/23/2006 | US20060040964 Eating disorders; psychological disorders; antidiabetic agents; cardiovascular disorders |
| 02/23/2006 | US20060040963 Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 02/23/2006 | US20060040957 Bicyclic pyrimidine matrix metalloproteinase inhibitors |
| 02/23/2006 | US20060040951 Use of 5-ht2 receptor antagonists for the treatment of sleep disorders |
| 02/23/2006 | US20060040950 Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| 02/23/2006 | US20060040940 Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands |
| 02/23/2006 | US20060040933 Antiinflammatory agents |
| 02/23/2006 | US20060040920 Crystal forms of olanzapine and processes for their preparation |
| 02/23/2006 | US20060040918 Benzo d!azepine derivatives for the treatment of neurological disorders |
| 02/23/2006 | US20060040910 Macrocycles useful in the treatment of Alzheimer's disease |
| 02/23/2006 | US20060040905 Formulation of nefopam and its use in the treatment of pain |
| 02/23/2006 | US20060040876 Modulation of peroxisome proliferator-activated receptors |
| 02/23/2006 | US20060040869 Pharmaceutically useful compounds |
| 02/23/2006 | US20060040331 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents |
| 02/23/2006 | US20060040266 Diagnostics and therapeutics for diseases associated with neuromedin u2 receptor (nmu2) |
| 02/23/2006 | US20060040265 Regulation of novel human asparagine-hydroxylases |
| 02/23/2006 | US20060039997 Multiparticulate formulations of lithium salts for oral administration suitable for once-a-day administration |
| 02/23/2006 | US20060039970 Tamper-resistant oral opioid agonist formulations |
| 02/23/2006 | US20060039962 Amphiphilic compounds and vesicles liposomes for organ-specified drug targeting |
| 02/23/2006 | US20060039959 Film-Shaped Mucoadhesive Administration Forms For Administering Cannabis Agents |
| 02/23/2006 | US20060039953 Water soluble polymer such as pullulan and an antimicrobial effective amount of thymol, methyl salicylate, eucalyptol and/or menthol; killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath |
| 02/23/2006 | US20060039918 Stress proteins and peptides and methods of use thereof |
| 02/23/2006 | US20060039917 Method for treating phantom pain by peripheral administration of a neurotoxin |
| 02/23/2006 | US20060039916 Method for treating complex regional pain by peripheral administration of a neurotoxin |
| 02/23/2006 | US20060039906 Humanized antibodies that sequester abeta peptide |
| 02/23/2006 | US20060039903 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 02/23/2006 | DE20023745U1 Method of modulating expression of an endogenous cellular gene in a cell to prevent gene activation or prevent repression of gene expression comprising contacting a target sequence with a zinc finger protein |
| 02/23/2006 | DE102004039373A1 Para-Alkyl-substituierte N-(4-Hydroxy-3-methoxy-benzyl)-zimtsäureamide und deren Verwendung zur Herstellung von Arzneimitteln Para-alkyl-substituted N- (4-hydroxy-3-methoxy-benzyl) -cinnamic acid amides and their use for the preparation of medicaments |
| 02/23/2006 | DE102004039280A1 1,5-Diphenyl-pyrazole 1,5-diphenyl-pyrazoles |
| 02/23/2006 | DE102004039065A1 New N-substituted 1-benzyl-1H-(1,2,3)-triazole-4-carboxamides, are dopamine and alpha-1 adrenergic receptor ligands useful for treating diseases of the urinary tract, vascular system or CNS |
| 02/23/2006 | DE102004034619A1 Substituierte Aminoverbindungen als 5-HT/NA Uptakehemmer Substituted amino compounds as 5-HT / NA Uptakehemmer |
| 02/23/2006 | CA2577386A1 Pulmonary delivery of a nerve agent neutralizing enzyme |
| 02/23/2006 | CA2577274A1 Anti-inflammatory agents |
| 02/23/2006 | CA2576156A1 Use of xenon as neuroprotectant in a neonatal subject |
| 02/23/2006 | CA2575979A1 Novel serotonin receptor ligands and their uses thereof |
| 02/23/2006 | CA2575848A1 Medicament for the treatment of central nervous system disorders |
| 02/23/2006 | CA2575826A1 Compounds and compositions useful as cathepsin s inhibitors |
| 02/23/2006 | CA2575785A1 5-ht7 receptor antagonists |
| 02/23/2006 | CA2575771A1 5-ht7 receptor antagonists |
| 02/23/2006 | CA2573819A1 Heterocyclic dye compounds for in vivo imaging and diagnosis of alzheimer's disease |
| 02/23/2006 | CA2573720A1 Netrin-related compositions and uses |
| 02/23/2006 | CA2573454A1 Use of flibanserin for the treatment of anorexia nervosa |
| 02/23/2006 | CA2478456A1 Combination therapy |
| 02/22/2006 | EP1627871A1 Cyclic aminophenyl sulfamate derivative |
| 02/22/2006 | EP1627869A1 Amide derivative |
| 02/22/2006 | EP1627639A2 Use of COX-2 inhibitors for the treatment of affective disorders |